TY  - JOUR
AU  - Cuneo, Antonio
AU  - Follows, George
AU  - Rigolin, Gian Matteo
AU  - Piciocchi, Alfonso
AU  - Tedeschi, Alessandra
AU  - Trentin, Livio
AU  - Perez, Angeles Medina
AU  - Coscia, Marta
AU  - Laurenti, Luca
AU  - Musuraca, Gerardo
AU  - Farina, Lucia
AU  - Delgado, Alfredo Rivas
AU  - Orlandi, Ester Maria
AU  - Galieni, Piero
AU  - Mauro, Francesca Romana
AU  - Visco, Carlo
AU  - Amendola, Angela
AU  - Billio, Atto
AU  - Marasca, Roberto
AU  - Chiarenza, Annalisa
AU  - Meneghini, Vittorio
AU  - Ilariucci, Fiorella
AU  - Marchetti, Monia
AU  - Molica, Stefano
AU  - Re, Francesca
AU  - Gaidano, Gianluca
AU  - Gonzalez, Marcos
AU  - Forconi, Francesco
AU  - Ciolli, Stefania
AU  - Cortelezzi, Agostino
AU  - Montillo, Marco
AU  - Smolej, Lukas
AU  - Schuh, Anna
AU  - Eyre, Toby A
AU  - Kennedy, Ben
AU  - Bowles, Kris M
AU  - Vignetti, Marco
AU  - de la Serna, Javier
AU  - Moreno, Carol
AU  - Foà, Robin
AU  - Ghia, Paolo
AU  - GIMEMA, European Research Initiative on CLL (ERIC) and UK CLL forum
PY  - 2018
DO  - 10.3324/haematol.2018.189837
UR  - http://hdl.handle.net/10668/12372
T2  - Haematologica
AB  - We performed an observational study on the efficacy of ben-damustine and rituximab (BR) as first salvage regimen in chronic lymphocytic leukemia (CLL). In an intention-to-treat analysis including 237 patients, the median progression-free survival...
LA  - en
KW  - Adenine
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Bendamustine Hydrochloride
KW  - Biomarkers, Tumor
KW  - Humans
KW  - Italy
KW  - Leukemia, Lymphocytic, Chronic, B-Cell
KW  - Middle Aged
KW  - Piperidines
KW  - Prognosis
KW  - Pyrazoles
KW  - Pyrimidines
KW  - Retreatment
KW  - Rituximab
KW  - Salvage Therapy
KW  - Survival Analysis
KW  - Treatment Outcome
KW  - United Kingdom
TI  - Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
TY  - research article
VL  - 103
ER  -